Hepatitis C with normal liver enzymes: to treat or not to treat. Con: most patients should not be treated.
Reddy
K Rajender
KR
University of Pennsylvania, USA.
D000410:Alanine Transaminase / Q000032:analysis*; D000998:Antiviral Agents / Q000627:therapeutic use*; D003657:Decision Making; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D019698:Hepatitis C, Chronic / Q000175:diagnosis* / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D008111:Liver Function Tests; D008297:Male; D011994:Recombinant Proteins; D012016:Reference Values; D012254:Ribavirin / Q000627:therapeutic use; D018570:Risk Assessment; D012720:Severity of Illness Index
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D012254:Ribavirin; D000410:Alanine Transaminase